195 related articles for article (PubMed ID: 23060293)
1. Structural exploration of (3S,6S)-6-benzhydryl-N-benzyltetrahydro-2H-pyran-3-amine analogues: identification of potent triple monoamine reuptake inhibitors as potential antidepressants.
Santra S; Gogoi S; Gopishetty B; Antonio T; Zhen J; Reith ME; Dutta AK
ChemMedChem; 2012 Dec; 7(12):2093-100. PubMed ID: 23060293
[TBL] [Abstract][Full Text] [Related]
2. Further structural exploration of trisubstituted asymmetric pyran derivatives (2S,4R,5R)-2-benzhydryl-5-benzylamino-tetrahydropyran-4-ol and their corresponding disubstituted (3S,6S) pyran derivatives: a proposed pharmacophore model for high-affinity interaction with the dopamine, serotonin, and norepinephrine transporters.
Zhang S; Fernandez F; Hazeldine S; Deschamps J; Zhen J; Reith ME; Dutta AK
J Med Chem; 2006 Jul; 49(14):4239-47. PubMed ID: 16821783
[TBL] [Abstract][Full Text] [Related]
3. Further structure-activity relationship studies on 4-((((3S,6S)-6-benzhydryltetrahydro-2H-pyran-3-yl)amino)methyl)phenol: identification of compounds with triple uptake inhibitory activity as potential antidepressant agents.
Gopishetty B; Hazeldine S; Santra S; Johnson M; Modi G; Ali S; Zhen J; Reith M; Dutta A
J Med Chem; 2011 Apr; 54(8):2924-32. PubMed ID: 21446715
[TBL] [Abstract][Full Text] [Related]
4. D-161, a novel pyran-based triple monoamine transporter blocker: behavioral pharmacological evidence for antidepressant-like action.
Dutta AK; Ghosh B; Biswas S; Reith ME
Eur J Pharmacol; 2008 Jul; 589(1-3):73-9. PubMed ID: 18561912
[TBL] [Abstract][Full Text] [Related]
5. Flexible and biomimetic analogs of triple uptake inhibitor 4-((((3S,6S)-6-benzhydryltetrahydro-2H-pyran-3-yl)amino)methyl)phenol: Synthesis, biological characterization, and development of a pharmacophore model.
Sharma H; Santra S; Debnath J; Antonio T; Reith M; Dutta A
Bioorg Med Chem; 2014 Jan; 22(1):311-24. PubMed ID: 24315194
[TBL] [Abstract][Full Text] [Related]
6. Development of potent dopamine-norepinephrine uptake inhibitors (DNRIs) based on a (2S,4R,5R)-2-benzhydryl-5-((4-methoxybenzyl)amino)tetrahydro-2H-pyran-4-ol molecular template.
Santra S; Sharma H; Vedachalam S; Antonio T; Reith M; Dutta A
Bioorg Med Chem; 2015 Feb; 23(4):821-8. PubMed ID: 25593099
[TBL] [Abstract][Full Text] [Related]
7. Discovery of novel trisubstituted asymmetric derivatives of (2S,4R,5R)-2-benzhydryl-5-benzylaminotetrahydropyran-4-ol, exhibiting high affinity for serotonin and norepinephrine transporters in a stereospecific manner.
Zhang S; Zhen J; Reith ME; Dutta AK
J Med Chem; 2005 Jul; 48(15):4962-71. PubMed ID: 16033275
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological and behavioral characterization of D-473, an orally active triple reuptake inhibitor targeting dopamine, serotonin and norepinephrine transporters.
Dutta AK; Santra S; Sharma H; Voshavar C; Xu L; Mabrouk O; Antonio T; Reith ME
PLoS One; 2014; 9(11):e113420. PubMed ID: 25427177
[TBL] [Abstract][Full Text] [Related]
9. The novel trisubstituted pyran derivative D-142 has triple monoamine reuptake inhibitory activity and exerts potent antidepressant-like activity in rodents.
Dutta AK; Gopishetty B; Gogoi S; Ali S; Zhen J; Reith M
Eur J Pharmacol; 2011 Dec; 671(1-3):39-44. PubMed ID: 21963455
[TBL] [Abstract][Full Text] [Related]
10. Novel Potent Dopamine-Norepinephrine and Triple Reuptake Uptake Inhibitors Based on Asymmetric Pyran Template and Their Molecular Interactions with Monoamine Transporters.
Santra S; Kortagere S; Vedachalam S; Gogoi S; Antonio T; Reith MEA; Dutta AK
ACS Chem Neurosci; 2021 Apr; 12(8):1406-1418. PubMed ID: 33844493
[TBL] [Abstract][Full Text] [Related]
11. Biaryl analogues of conformationally constrained tricyclic tropanes as potent and selective norepinephrine reuptake inhibitors: synthesis and evaluation of their uptake inhibition at monoamine transporter sites.
Zhou J; Zhang A; Kläss T; Johnson KM; Wang CZ; Ye YP; Kozikowski AP
J Med Chem; 2003 May; 46(10):1997-2007. PubMed ID: 12723962
[TBL] [Abstract][Full Text] [Related]
12. The extracts of Fructus Akebiae, a preparation containing 90% of the active ingredient hederagenin: serotonin, norepinephrine and dopamine reuptake inhibitor.
Jin ZL; Gao N; Zhou D; Chi MG; Yang XM; Xu JP
Pharmacol Biochem Behav; 2012 Jan; 100(3):431-9. PubMed ID: 22005599
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and preliminary SAR study of 3- and 6-side-chain-extended tetrahydro-pyran analogues of cis- and trans-(6-benzhydryl-tetrahydropyran-3-yl)-benzylamine.
Zhang S; Zhen J; Reith ME; Dutta AK
Bioorg Med Chem; 2006 Jun; 14(11):3953-66. PubMed ID: 16481172
[TBL] [Abstract][Full Text] [Related]
14. Preclinical pharmacology of TP1, a novel potent triple reuptake inhibitor with antidepressant properties.
Tian JW; Jiang WL; Zhong Y; Meng Q; Gai Y; Zhu HB; Hou J; Xing Y; Li YX
Neuroscience; 2011 Nov; 196():124-30. PubMed ID: 21925241
[TBL] [Abstract][Full Text] [Related]
15. Structure-activity relationship studies of 4-[2-(diphenylmethoxy)ethyl]-1-benzylpiperidine derivatives and their N-analogues: evaluation of O-and N-analogues and their binding to monoamine transporters.
Dutta AK; Fei XS; Beardsley PM; Newman JL; Reith ME
J Med Chem; 2001 Mar; 44(6):937-48. PubMed ID: 11300876
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological and behavioral analysis of the effects of some bivalent ligand-based monoamine reuptake inhibitors.
Tamiz AP; Bandyopadhyay BC; Zhang J; Flippen-Anderson JL; Zhang M; Wang CZ; Johnson KM; Tella S; Kozikowski AP
J Med Chem; 2001 May; 44(10):1615-22. PubMed ID: 11334571
[TBL] [Abstract][Full Text] [Related]
17. MDMA (Ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment.
Verrico CD; Miller GM; Madras BK
Psychopharmacology (Berl); 2007 Jan; 189(4):489-503. PubMed ID: 16220332
[TBL] [Abstract][Full Text] [Related]
18. Structural requirements for 2,4- and 3,6-disubstituted pyran biomimetics of cis-(6-benzhydryl-piperidin-3-yl)-benzylamine compounds to interact with monoamine transporters.
Zhang S; Zhen J; Reith ME; Dutta AK
Bioorg Med Chem; 2004 Dec; 12(23):6301-15. PubMed ID: 15519172
[TBL] [Abstract][Full Text] [Related]
19. Further structurally constrained analogues of cis-(6-benzhydrylpiperidin-3-yl)benzylamine with elucidation of bioactive conformation: discovery of 1,4-diazabicyclo[3.3.1]nonane derivatives and evaluation of their biological properties for the monoamine transporters.
Kolhatkar R; Cook CD; Ghorai SK; Deschamps J; Beardsley PM; Reith ME; Dutta AK
J Med Chem; 2004 Oct; 47(21):5101-13. PubMed ID: 15456254
[TBL] [Abstract][Full Text] [Related]
20. Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.
Froimowitz M; Wu KM; Moussa A; Haidar RM; Jurayj J; George C; Gardner EL
J Med Chem; 2000 Dec; 43(26):4981-92. PubMed ID: 11150168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
